Table 2.
Quantitative targeted assay analysis.
| Discharge | Survivor | Nonsurvivor | |||
|---|---|---|---|---|---|
| Day1 | Day3 | Day1 | Day3 | ||
| Amino acids | |||||
| Alanine | 317 ± 26.8 | 195 ± 20.2* | 209 ± 20.1 | 218 ± 25.0* | 516 ± 210 |
| Arginine | 91.6 ± 10.0 | 73.9 ± 10.3 | 76.9 ± 9.4 | 55.4 ± 9.2* | 55.7 ± 9.8* |
| Phenylalanine | 81.4 ± 6.8 | 120.8 ± 24.8 | 103.9 ± 18.6 | 120.4 ± 14.7 | 185.7 ± 35.4*,# |
| Glycine | 333.8 ± 22.6 | 233.2 ± 19.5* | 236.6 ± 24.3 | 202.5 ± 11.9* | 301.7 ± 71.3 |
| Proline | 194.7 ± 15.2 | 169.8 ± 18.4 | 165.7 ± 16.6 | 181.5 ± 24.6 | 290.6 ± 45.8# |
| Serine | 111.0 ± 7.4 | 85.0 ± 7.4 | 94.6 ± 8.5 | 59.3 ± 3.7* | 77.1 ± 8.5* |
| Threonine | 155.4 ± 12.6 | 104.9 ± 11.9* | 125.3 ± 17.5 | 92.3 ± 9.2* | 152.3 ± 35.1 |
| AA Derivatives | |||||
| Asymmetric dimethylarginine | 0.61 ± 0.03 | 0.61 ± 0.06 | 0.55 ± 0.04 | 0.71 ± 0.1 | 0.84 ± 0.08# |
| Creatinine | 161.4 ± 48.7 | 221.4 ± 75.2 | 211.7 ± 69.9 | 293.9 ± 47.5 | 339.0 ± 47.2*,# |
| Sarcosine | 7.7 ± 0.7 | 5.1 ± 0.5* | 5.3 ± 0.4 | 5.3 ± 0.6* | 6.2 ± 0.7 |
| t4-OH-Pro | 14.5 ± 1.8 | 12.9 ± 2.9 | 8.4 ± 1.1 | 15.1 ± 3.0 | 20.9 ± 4.0# |
| NAD+ | |||||
| Tryptophan | 58.2 ± 5.0 | 42.6 ± 4.2 | 47.7 ± 5.7 | 31.0 ± 3.4* | 39.0 ± 5.2 |
| Kynurenine | 3.5 ± 0.4 | 4.7 ± 0.8 | 4.0 ± 0.6 | 11.7 ± 4.1* | 14.0 ± 3.8*,# |
| Carnitine esters | |||||
| Acetylcarnitine | 7.0 ± 0.7 | 9.9 ± 1.5 | 9.1 ± 1.6 | 23.6 ± 6.5* | 19.6 ± 4.4* |
| C3-DC (C4-OH) | 0.14 ± 0.01 | 0.19 ± 0.03 | 0.16 ± 0.02 | 0.33 ± 0.1* | 0.30 ± 0.05*,# |
| C6 (C4:1-DC) | 0.09 ± 0.00 | 0.12 ± 0.02 | 0.12 ± 0.02 | 0.23 ± 0.1* | 0.25 ± 0.05*,# |
| Octanoylcarnitine | 0.18 ± 0.01 | 0.19 ± 0.02 | 0.21 ± 0.03 | 0.32 ± 0.1 | 0.35 ± 0.06* |
| Acyl-GPCs | |||||
| lysoPC a C16:0 | 74.2 ± 7.5 | 34.4 ± 4.0* | 48.0 ± 6.8 | 16.4 ± 2.4*,# | 15.5 ± 3.4*,# |
| lysoPC a C16:1 | 2.62 ± 0.30 | 1.07 ± 0.10* | 1.53 ± 0.21* | 0.58 ± 0.1*,# | 0.61 ± 0.12*,# |
| lysoPC a C17:0 | 1.37 ± 0.15 | 0.63 ± 0.06* | 0.87 ± 0.12 | 0.42 ± 0.0* | 0.41 ± 0.08*,# |
| lysoPC a C18:0 | 20.2 ± 2.4 | 9.8 ± 1.4* | 13.4 ± 2.1 | 4.9 ± 0.6*,# | 5.3 ± 1.5*,# |
| lysoPC a C18:1 | 21.0 ± 4.3 | 8.8 ± 0.9* | 13.3 ± 2.0 | 4.3 ± 0.5*,# | 5.1 ± 1.2*,# |
| lysoPC a C18:2 | 29.9 ± 4.3 | 10.8 ± 1.6* | 17.5 ± 3.3 | 4.8 ± 0.5*,# | 5.6 ± 1.7*,# |
| lysoPC a C20:3 | 2.49 ± 0.42 | 1.23 ± 0.11* | 1.48 ± 0.19 | 0.92 ± 0.1* | 0.98 ± 0.18* |
| lysoPC a C20:4 | 8.7 ± 0.9 | 4.2 ± 0.5* | 5.5 ± 0.9 | 2.1 ± 0.2*,# | 2.1 ± 0.5*,# |
| Phosphatidyl-cholines | |||||
| PC aa C32:0 | 16.7 ± 2.4 | 15.9 ± 1.9 | 15.8 ± 1.6 | 32.5 ± 8.6 | 50.5 ± 25.6# |
| PC ae C30:0 | 0.40 ± 0.03 | 0.44 ± 0.05 | 0.40 ± 0.03 | 0.69 ± 0.1 | 0.81 ± 0.14*,# |
| PC ae C40:1 | 0.98 ± 0.15 | 0.55 ± 0.05* | 0.72 ± 0.11 | 0.46 ± 0.1* | 0.57 ± 0.21 |
| Bile acids | |||||
| Taurolithocholic acid sulfate | 0.09 ± 0.01 | 0.21 ± 0.04 | 0.23 ± 0.09 | 0.71 ± 0.4 | 0.90 ± 0.34* |